FoghornTherapeutics Inc. (FHTX) , a clinical-stage company, announced that its pre-clinical candidate, FHD- 909, has been selected by Eli Lilly (LLY) for clinical development under the December 2021 strategic collaboration agreement to create novel oncology medicines. Per the terms of the December 2021 agreement, Foghorn and Lilly are co-developing and co-commercializing LLY’s Selective BRM oncology program and an additional undisclosed oncology target. Both companies are sharing the costs of development eq ...